To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Institute | Diagnosis and innovative treatment | Mass spectrometry | Biomarkers
Medicines and Healthcare Technologies Department of the Frédéric Joliot Institute for Life Sciences, directed by Christophe Junot, carries out research in Diagnostic and Therapeutic Innovation, in particular in the Molecular Innovation area, around four thematic axes :
It is affiliated with two LabEx: the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT) and the Laboratory of Excellence in Chemistry of Multifunctional Molecular Architectures and Materials (CHARM3AT).
A Li2D team has released the peptidomic profile of the virus that causes monkeypox, which they established using tandem mass spectrometry. These data should help to better understand the evolution of the epidemic and allow the creation of targeted tests to potentially detect the threat more quickly and prevent a new epidemic.
A consortium of researchers, including SPI/DMTS metabolomics specialists, presents PeakForest, a database of NMR and mass spectra, which provides storage and annotation services for spectra of reference compounds and metabolic profiles of biological matrices. An open resource to address the evolving needs of the discipline.
A team from SIMoS (DMTS) identifies and characterizes a toxin isolated from black mamba venom, whose specific anticholinergic properties at the type 2 acetylcholine receptor, a regulator of arterial tone, position it as a potential drug candidate for the treatment of cardiovascular diseases.
Researchers from SIMoS and SPI (DMTS) demonstrate that molecular engineering of llama antibodies, capable of neutralizing SARS-CoV-1, allows to obtain optimized antibodies with very high affinities for SARS-CoV-2 and its variants, the culprits of the Covid-19 epidemic.
A team from SIMoS, in collaboration with the SCBM (DMTS), has developed an original bioanalytical approach based on the double 14C-3H isotopic labeling of an antibody-drug conjugate, allowing the simultaneous in vivo monitoring of the two components in mouse models as well as their precise quantification in the organs.
Researchers at the LERI together with the AP-HP have developed 2 rapid and inexpensive immunological tests to detect antibiotic resistance. The novelty: the tests detect the activity of bacterial enzymes that hydrolyze extended-spectrum cephalosporins.
SIMoS team, in collaboration with Bicêtre Hospital, shows that certolizumab pegol, a pegylated monoclonal antibody fragment for anti-inflammatory use, is less likely to trigger an adverse immune response than the non-pegylated form.
To carry out their activities, researchers of Medicines and Healthcare Technologies Department have access to several research platforms, two of which certified
IBiSA, within the Frédéric Joliot Institute for Life Sciences:
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.